Clinical Trial Update: A Dose-Escalation Study in Participants With Recurrent Malignant Glioma [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation trial in recurrent malignant glioma conducted by Eli Lilly has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Snippet

Sponsor: Eli Lilly and Company | Conditions: Glioma | Phase 1 | Status: COMPLETED